UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D. C. 20549

 


 

FORM 8-K

 

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): May 6, 2016

 

ABBVIE INC.

(Exact name of registrant as specified in its charter)

 


 

Delaware

 

001-35565

 

32-0375147

(State or other Jurisdiction

 

(Commission File Number)

 

(IRS Employer

of Incorporation)

 

 

 

Identification No.)

 


 

1 North Waukegan Road

North Chicago, Illinois 60064-6400

(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code: (847) 932-7900

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o      Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o      Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o      Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR    240.14d-2(b))

 

o      Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 



 

Item 5.07.  Submission of Matters to a Vote of Security Holders.

 

AbbVie Inc. (“AbbVie”) held its Annual Meeting of Stockholders on May 6, 2016.  The following is a summary of the matters voted on at that meeting.

 

(1)           The stockholders elected AbbVie’s Class I Directors with terms expiring in 2019, as follows:

 

Name

 

For

 

Withheld

 

Broker Non-Votes

 

William H.L. Burnside

 

1,096,503,500

 

27,564,642

 

252,971,981

 

Brett J. Hart

 

1,114,820,916

 

9,247,226

 

252,971,981

 

Edward J. Rapp

 

1,100,224,431

 

23,843,711

 

252,971,981

 

 

(2)           The stockholders ratified the appointment of Ernst & Young LLP as AbbVie’s independent registered public accounting firm for 2016, as follows:

 

For

 

Against

 

Abstain

 

1,340,179,406

 

33,985,696

 

2,875,021

 

 

(3)           The stockholders approved, on an advisory basis, the compensation of AbbVie’s named executive officers listed in the proxy statement for the 2016 annual meeting, as follows:

 

For

 

Against

 

Abstain

 

Broker Non-Votes

 

1,060,483,805

 

56,453,483

 

7,130,854

 

252,971,981

 

 

(4)           The stockholders did not approve the management proposal regarding the annual election of directors, as follows:

 

For

 

Against

 

Abstain

 

Broker Non-Votes

 

1,113,543,016

 

5,999,908

 

4,525,218

 

252,971,981

 

 

(5)           The stockholders approved the material terms of performance goals under the AbbVie Performance Incentive Plan, as follows:

 

For

 

Against

 

Abstain

 

Broker Non-Votes

 

1,089,198,311

 

28,289,479

 

6,580,352

 

252,971,981

 

 

(6)           The stockholders did not approve a stockholder proposal regarding a drug disposal report, as follows:

 

For

 

Against

 

Abstain

 

Broker Non-Votes

 

71,469,196

 

880,815,791

 

171,783,155

 

252,971,981

 

 

2



 

(7)           The stockholders did not approve a stockholder proposal regarding a lobbying report, as follows:

 

For

 

Against

 

Abstain

 

Broker Non-Votes

 

284,683,921

 

683,454,925

 

155,929,296

 

252,971,981

 

 

3



 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

 

ABBVIE INC.

 

 

 

 

 

 

 

 

Date:   May 10, 2016

 

By:

/s/ Laura J. Schumacher

 

 

 

Laura J. Schumacher

 

 

 

Executive Vice President, External Affairs,

 

 

 

General Counsel, and Corporate Secretary

 

4